News Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:47:03 2026-05-19 pm EDT			5-day change	1st Jan Change
229.90 ^USD	+0.43%		+2.45%	+11.02%

12:35pm	Johnson & Johnson Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 11:30 AM
04:29am	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT

All News

Mentions Relevance

12:35pm	Johnson & Johnson Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 11:30 AM
May. 18	Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 15	Soros Fund Management reports share stake in Mastercard, Berkshire Hathaway & J&J	RE
May. 14	Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation	PR
May. 14	Rising Scrutiny Of Employer Health Plan Administration: ERISA Fiduciary Litigation, Federal Transparency Initiatives, State Enforcement, And Compliance Considerations	AQ
May. 13	Leerink Partners Upgrades Johnson & Johnson to Outperform From Market Perform, Adjusts PT to $265 From $252	MT
May. 12	Johnson & Johnson : showcases hematology leadership with 30+ presentations at the 2026 European Hematology Association (EHA) Congress	PU
May. 12	Johnson & Johnson Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11:20 AM
May. 12	Johnson & Johnson Launches Shockwave C2 Aero Coronary IVL Catheter	MT
May. 12	Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter	BU
May. 12	Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter	CI
May. 11	Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
May. 11	Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP	PR
May. 07	Johnson & Johnson launches "Generation Fine," a new movement encouraging patients to expect more from depression treatment and aim for remission	RE
May. 07	Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission	PR
May. 07	Breach Of Contract, IP Rights, And Irreparable Harm: Lessons From The Third Circuit’s Stelara Decision	AQ
May. 05	CVS to drop J&J's Stelara from its main formularies	RE
May. 05	Johnson & Johnson Announces Caplyta Shows Greatest Improvement Across Key Efficacy Outcomes Among Adjunctive MDD Treatments In New Network Meta-Analysis	CI
May. 05	Johnson & Johnson : study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease	PU
May. 05	Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease	PR
May. 05	Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease	PR
May. 05	Johnson & Johnson Announces Phase 2b Data For JNJ-4804 Co-Antibody Therapy In Refractory Inflammatory Bowel Disease	CI
May. 05	Johnson & Johnson Announces Positive Phase 3 Fuzion Study Results For Tremfya In Perianal Fistulizing Crohn?s Disease	CI